Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Bonanni

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of Cheminformatics|November 8, 2022
Development of machine learning classifiers to predict compound activity on prostate cancer cell linesDavide Bonanni, Luca Pinzi, Giulio Rastelli
Journal of Medicinal Chemistry|January 16, 2020
Computational Method for Structure-Based Analysis of SAR TransferDavide Bonanni, Marco L Lolli, Jürgen Bajorath
ACS Omega|September 9, 2021
Hydroxamic Acid Derivatives: From Synthetic Strategies to Medicinal Chemistry ApplicationsAndrea Citarella, Davide Moi, Luca Pinzi, et al.
Current Medicinal Chemistry|September 3, 2021
Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90)Davide Bonanni, Andrea Citarella, Davide Moi, et al.
RSC Advances|April 15, 2022
Synthesis of potent and selective HDAC6 inhibitors led to unexpected opening of a quinazoline ringDavide Moi, Andrea Citarella, Davide Bonanni, et al.
European Journal of Medicinal Chemistry|August 26, 2023
Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancerDavide Moi, Davide Bonanni, Silvia Belluti, et al.
Medchemcomm|November 2, 2019
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinityAna R N Santos, Helen M Sheldrake, Ali I M Ibrahim, et al.
European Journal of Medicinal Chemistry|September 8, 2017
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approachAgnese C Pippione, Alessandro Giraudo, Davide Bonanni, et al.
European Journal of Medicinal Chemistry|June 26, 2018
Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agentsLaurent R Chiarelli, Matteo Mori, Daniela Barlocco, et al.
European Journal of Medicinal Chemistry|March 31, 2018
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acidAgnese Chiara Pippione, Irene Maria Carnovale, Davide Bonanni, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Cheminformatics|November 8, 2022
Development of machine learning classifiers to predict compound activity on prostate cancer cell linesDavide Bonanni, Luca Pinzi, Giulio Rastelli
Journal of Medicinal Chemistry|January 16, 2020
Computational Method for Structure-Based Analysis of SAR TransferDavide Bonanni, Marco L Lolli, Jürgen Bajorath
ACS Omega|September 9, 2021
Hydroxamic Acid Derivatives: From Synthetic Strategies to Medicinal Chemistry ApplicationsAndrea Citarella, Davide Moi, Luca Pinzi, et al.
Current Medicinal Chemistry|September 3, 2021
Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90)Davide Bonanni, Andrea Citarella, Davide Moi, et al.
RSC Advances|April 15, 2022
Synthesis of potent and selective HDAC6 inhibitors led to unexpected opening of a quinazoline ringDavide Moi, Andrea Citarella, Davide Bonanni, et al.
European Journal of Medicinal Chemistry|August 26, 2023
Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancerDavide Moi, Davide Bonanni, Silvia Belluti, et al.
Medchemcomm|November 2, 2019
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinityAna R N Santos, Helen M Sheldrake, Ali I M Ibrahim, et al.
European Journal of Medicinal Chemistry|September 8, 2017
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approachAgnese C Pippione, Alessandro Giraudo, Davide Bonanni, et al.
European Journal of Medicinal Chemistry|June 26, 2018
Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agentsLaurent R Chiarelli, Matteo Mori, Daniela Barlocco, et al.
European Journal of Medicinal Chemistry|March 31, 2018
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acidAgnese Chiara Pippione, Irene Maria Carnovale, Davide Bonanni, et al.
Pageof 2